Pfizer’s turnover soars in Q1, boosted by anticovid vaccine

The American laboratory Pfizer invoiced 25.7 billion dollars in the first quarter of 2022, an increase of 77% compared to the same period last year, largely thanks to the sales of its anticovid vaccine.

The firm also maintained the sales forecast for its Paxlovid anticovid pill of 22,000 million dollars in the year.

Meanwhile, Pfizer revised down its full-year profit estimate, mainly due to a change in accounting standards.

$(document).ready(function() {

$("ul.tabscom li").click(function () { $("ul.tabscom li").removeClass("active"); $(this).addClass("active"); $(".tab_content").hide();

var activeTab = $(this).find("a").attr("href"); $(activeTab).show(); return false; });

//$(".tab_content").hide(); //$("#fb").addClass("active").show(); //$("#fb").click(); //$(".tab_content:first").show();

});



Source link

Previous Story

Former Argentine taekwondo coach convicted of child sexual exploitation

Latest from Panama